Geno J. Germano - 19 Oct 2026 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc. (ELOX)

Reporting relationship: Director
Issuer ticker: ELOX
Reported as of: 19 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Oct 2026, 19:33:22 UTC
Prior SEC filing: 29 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Sumit Aggarwal, Attorney-in-Fact

Filing notes and source

Key filing fact

Geno J. Germano filed Form 4 for Eloxx Pharmaceuticals, Inc. (ELOX) on 21 Oct 2026.

Key facts

This page summarizes Geno J. Germano's Form 4 filing for Eloxx Pharmaceuticals, Inc. (ELOX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Oct 2026, 19:33.

Change

Previous filing in this sequence was filed on 29 Sep 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001424383 Primary reporting owner

Germano Geno J

Relationship: Director
Address: C/O ELOXX PHARMACEUTICALS, INC., P.O. BOX 274, ARLINGTON
Signature: /s/ Sumit Aggarwal, Attorney-in-Fact
Signature date: 21 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELOX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +13,587
Change %
Price: $0.000000^*
Shares after: 13,587
Date: 19 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,587
Exercise price: $12.50
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option will vest, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date, in 24 substantially equal monthly installments on the last day of the month so that the option will be fully vested and exercisable on the last day of the month of the second anniversary of the grant date.